HomeOGN • NYSE
add
Organon & Co
Previous close
$18.71
Day range
$18.20 - $18.73
Year range
$10.84 - $24.79
Market cap
4.71B USD
Avg Volume
2.19M
P/E ratio
4.61
Dividend yield
6.08%
Primary exchange
NYSE
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 1.60B | 7.61% |
Operating expense | 601.00M | -1.48% |
Net income | 546.00M | 405.56% |
Net profit margin | 34.17 | 370.01% |
Earnings per share | 0.88 | 8.64% |
EBITDA | 374.00M | 9.36% |
Effective tax rate | -425.00% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 693.00M | -1.84% |
Total assets | 12.06B | 10.07% |
Total liabilities | 12.13B | 2.37% |
Total equity | -70.00M | — |
Shares outstanding | 255.64M | — |
Price to book | -69.30 | — |
Return on assets | 6.81% | — |
Return on capital | 9.28% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | 546.00M | 405.56% |
Cash from operations | 397.00M | 48.69% |
Cash from investing | -81.00M | -32.79% |
Cash from financing | -77.00M | 6.10% |
Net change in cash | 279.00M | 34.78% |
Free cash flow | 322.62M | 169.13% |
About
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia. Organon produces all its products outside of the United States but gets a third of its revenue from the United States. Organon & Co. is an example of increasing women's representation on Wall Street with over 50% of its board of directors and executive leadership being female. Wikipedia
Founded
2020
Headquarters
Website
Employees
10,000
